CINECA IRIS Institutional Research Information System

MARTINELLI, ADRIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.205
AS - Asia 7.967
EU - Europa 6.487
SA - Sud America 1.101
AF - Africa 281
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 8
Totale 33.061
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.696
CN - Cina 2.859
IT - Italia 2.138
SG - Singapore 2.079
HK - Hong Kong 1.158
SE - Svezia 1.149
BR - Brasile 934
DE - Germania 814
BG - Bulgaria 589
TR - Turchia 515
CA - Canada 426
VN - Vietnam 400
GB - Regno Unito 376
UA - Ucraina 304
RU - Federazione Russa 274
KR - Corea 268
FI - Finlandia 264
IN - India 211
FR - Francia 172
CH - Svizzera 113
JP - Giappone 84
BD - Bangladesh 80
AT - Austria 70
BE - Belgio 59
CI - Costa d'Avorio 50
AR - Argentina 48
IQ - Iraq 47
SN - Senegal 42
ZA - Sudafrica 42
PK - Pakistan 41
SA - Arabia Saudita 39
ID - Indonesia 38
MA - Marocco 38
MX - Messico 32
UZ - Uzbekistan 31
VE - Venezuela 30
ES - Italia 29
EC - Ecuador 27
PL - Polonia 21
GR - Grecia 19
IR - Iran 19
NG - Nigeria 19
NL - Olanda 19
CO - Colombia 18
KE - Kenya 17
EG - Egitto 16
TN - Tunisia 15
PY - Paraguay 13
IE - Irlanda 12
JM - Giamaica 12
UY - Uruguay 11
JO - Giordania 10
KZ - Kazakistan 10
AU - Australia 9
CL - Cile 9
IL - Israele 9
RO - Romania 9
AE - Emirati Arabi Uniti 8
DO - Repubblica Dominicana 8
TT - Trinidad e Tobago 8
AL - Albania 7
DZ - Algeria 7
NP - Nepal 7
PE - Perù 7
BY - Bielorussia 6
ET - Etiopia 6
AZ - Azerbaigian 5
BJ - Benin 5
CR - Costa Rica 5
CZ - Repubblica Ceca 5
OM - Oman 5
PT - Portogallo 5
DK - Danimarca 4
KW - Kuwait 4
LT - Lituania 4
PA - Panama 4
PH - Filippine 4
PS - Palestinian Territory 4
TW - Taiwan 4
AO - Angola 3
BA - Bosnia-Erzegovina 3
BB - Barbados 3
BO - Bolivia 3
EU - Europa 3
GE - Georgia 3
HU - Ungheria 3
LB - Libano 3
NZ - Nuova Zelanda 3
SI - Slovenia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BH - Bahrain 2
BN - Brunei Darussalam 2
CY - Cipro 2
EE - Estonia 2
GA - Gabon 2
GH - Ghana 2
GT - Guatemala 2
HN - Honduras 2
KG - Kirghizistan 2
Totale 33.008
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.270
Ann Arbor 2.075
Ashburn 1.488
Houston 1.406
Fairfield 1.257
Singapore 1.196
Hong Kong 1.150
Chandler 1.008
Santa Clara 795
Serra 634
Milan 593
Sofia 588
Dallas 538
Seattle 526
Beijing 513
Chengdu 513
Shanghai 500
Wilmington 437
Jacksonville 392
Izmir 380
Cambridge 373
Ottawa 358
New York 339
Hefei 336
Seoul 258
Boardman 248
Princeton 241
Los Angeles 224
Lawrence 217
Nanjing 202
Medford 180
Dong Ket 163
Des Moines 142
Dearborn 118
Marseille 107
Bern 103
Istanbul 96
Buffalo 90
The Dalles 89
Nanchang 88
Redondo Beach 88
Columbus 80
Florence 79
Council Bluffs 70
São Paulo 67
Boulder 66
Jüchen 65
San Diego 65
Tokyo 63
London 59
Redwood City 59
Vienna 55
Munich 52
Abidjan 50
Rome 48
Chicago 47
Brussels 46
Dakar 42
Ho Chi Minh City 40
Kunming 40
Nürnberg 37
Belo Horizonte 36
Kansas City 36
Rio de Janeiro 36
Pune 35
Shenyang 35
Frankfurt am Main 33
Ogden 33
Jiaxing 31
Pisa 31
Changsha 30
Tianjin 30
Dhaka 29
Hebei 29
Guangzhou 28
Tashkent 27
Detroit 26
Hanoi 26
Norwalk 26
Falls Church 25
Hangzhou 25
Jakarta 25
San Jose 25
Turku 24
Bremen 23
Fuzhou 23
San Francisco 23
Casablanca 22
Düsseldorf 22
Baghdad 21
New Delhi 19
Phoenix 19
Warsaw 19
Washington 19
Toronto 18
Lagos 17
Auburn Hills 16
Indiana 16
Orange 16
Brasília 15
Totale 24.438
Salva come PNG Salva come JPEG
Nome #
null 595
1,2,3-Triazolo[1,5-a][1,3]benzodiazepine a new heterocyclic system: Synthesis, benzodiazepine receptor binding and theoretical calculations 318
4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors 315
Chimica - VI Edizione Copyright © 2017, EdiSES srl - Napoli 280
Synthesis and 3D QSAR of New Pyrazolo[3,4-b]pyridines: Potent and Selective Inhibitors of A1 Adenosine Receptors 265
Phenylpropanoids and flavonoids from Phlomis kurdica as inhibitors of human lactate dehydrogenase. 252
Receptor-based virtual screening evaluation for the identification of estrogen receptor β ligands 251
THERMODYNAMIC PROPERTIES OF ORGANIC COMPOUNDS IN AQUEOUS-SOLUTIONS - APPARENT MOLAL HEAT-CAPACITIES OF AMINES AND ETHERS 233
1,2,3-triazolo[1.5-a]quinazolines: synthesis, benzodiazepine receptor binding and theoretical calculations 232
Synthesis and biological evaluation of non-glucose glycoconjugated N-hydroyxindole class LDH inhibitors as anticancer agents 227
Identification of Lactate Dehydrogenase 5 Inhibitors using Pharmacophore- Driven Consensus Docking 225
X-ray analisis, theoretical studies and a-adrenergic biopharmacological properties of 1-(2,5-dimethoxyphenyl)-2-aminoethanol and its morpholine analogue 223
1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. 223
Reliability analysis and optimization of the consensus docking approach for the development of virtual screening studies 218
CONFORMATIONAL STUDY OF ALPHA-BLOCKING ADRENERGIC-DRUGS WITH BENZODIOXANE STRUCTURE 213
Targeting Different Transthyretin Binding Sites with Unusual Natural Compounds 211
MOLECULAR-ORBITAL STUDIES ON MECHANISM OF DRUG-RECEPTOR INTERACTION .2. BETA-ADRENERGIC DRUGS - APPROACH TO EXPLAIN ROLE OF AROMATIC MOIETY 209
X-Ray analysis, theoretical studies and alfa-adrenergic biopharmacological properties of 1-(2,5-dimethoxyphenyl)-2-aminoethanol and its morpholine analogue. 208
A Virtual Screening Study for Lactate Dehydrogenase 5 Inhibitors by using a Pharmacophore-Based Approach 204
Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors 204
N-ALKYL-NOR-TROPINE ESTERS OF 2-PHENYL-CYCLOHEXENIC ACIDS AS NEW BRONCHODILATOR AGENTS - EFFECT OF STRUCTURAL AND CONFORMATIONAL MODIFICATIONS ON AFFINITY FOR MUSCARINIC RECEPTORS 201
1,2-disubstituted cyclohexane derived tripeptide aldehydes as novel selective thrombin inhibitors 200
Role of the acyloxymethyl moiety in eliciting the adrenergic ß-blocking activity of 3-acyloxypropanolamines 196
Identification of a new STAT3 dimerization inhibitor through a pharmacophore-based virtual screening approach 196
Synthesis of Anthranylaldoxime Derivatives as Estrogen Receptor Ligands and Computational Prediction of Binding Modes 195
An overview of recent developments in GPCR modelling: methods and validation 193
Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors 192
CONFORMATIONALLY RESTRAINED ANALOGS OF SYMPATHOMIMETIC CATECHOLAMINES - SYNTHESIS AND ADRENERGIC ACTIVITY OF TETRAHYDROBENZOCYCLOHEPTENE DERIVATIVES 192
The [(Methyloxy)imino]methyl Moiety as a Bioisoster of Aryl. A Novel Class of Completely Aliphatic Beta-Adrenergic Receptor Antagonists 192
Rational Development of MAGL Inhibitors 192
D3 dopamine receptor subtype: which binding modes for such different ligands?, 190
Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands 190
Dual Inhibitors of Matrix Metalloproteinases and Carbonic Anhydrases: Iminodiacetyl-Based Hydroxamate-Benzenesulfonamide Conjugates 189
Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands 187
Discovery of N-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform a (LDH-A) as Starvation Agents against Cancer Cells 187
5-Amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a Versatile Scaffold to Obtain Potent and Selective A3 Adenosine Receptor Antagonists 186
A CONFORMATIONAL APPROACH TO HISTAMINE H-2-RECEPTOR ANTAGONISTS 185
Rational design, synthesis, biological evaluation and labelling of selective cannabinoid CB2 receptor agonists as anticancer agents 185
Synthesis and antimicrobial properties of substituted 3-aminoxy-(E)-2-methoxyiminopropionyl penicillins and cephalosporins 184
Structural optimization of 4-chlorobenzoylpiperidine derivatives for the development of potent, reversible and selective monoacylglycerol lipase (MAGL) inhibitors 184
Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors 183
COMPOUNDS INHIBITING THE ENZYME LACTATE DEHYDROGENASE (LDH), PHARMACEUTICAL COMPOSITIONS AND USES THEREOF 183
SYNTHESIS, ANTIINFLAMMATORY ACTIVITY AND MOLECULAR-ORBITAL STUDIES OF A SERIES OF BENZYLIDENEAMINOXYPROPIONIC ACIDS SUBSTITUTED ON THE PHENYL RING 181
Antiproliferative oxime derivatives that inhibit glucose transporter 1 (GLUT1) in cancer cells 181
Identification of new FYN kinase inhibitors using a FLAP-based approach 181
Conformationally Restrained Analogs of Sympathomimetic Catecholamines. Synthesis, Conformational Analysis, and Adrenergic Activity of Isochroman Derivatives 181
Computational studies of EGFR inhibitors: Docking, 3D-QSAR analysis and virtual screening evaluation 180
D3 dopamine receptor subtype: which binding modes for such different ligands? 179
Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors 179
Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides 178
Synthesis of stable analogues of geranylgeranyl diphosphate possessing a (Z,E,E)-geranylgeranyl side chain, docking analysis, and biological assays for prenyl protein transferase inhibition 177
N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity 177
Design, Synthesis and biological evaluation of new 1,8-naphthyridin-4(1h)-on-3-carboxamide and quinolin-4(1h)-on-3-carboxamide derivatives as CB2 selective agonists 176
Synthesis and ß-adrenergic properties of (E)-N-[3-(alkylamino)-2- hydroxypropilidene](methyloxy)amines substituted with an aromatic group on their [(methyloxy)imino]methyl moiety (MOIMM): an investigation into the biopharmacological effects of an aryl substitution in the class of MOIM ß-blocking drugs. 175
Conformationally restrained ß-blocking oxime ethers. 2. Synthesis and ß-adrenergic properties of diastereoisomeric anti and syn 2-(5’-(3’-aryl-substituted)isoxazolidinyl)-N-alkylethanolamines 174
Dual Targeting of the Warburg Effect with a Glucose-Conjugated Lactate Dehydrogenase Inhibitor 174
Highly Selective Salicylketoxime-Based Estrogen Receptor β Agonists Display Antiproliferative Activities in a Glioma Model 174
MOLECULAR DESIGN, SYNTHESIS, AND ANTIINFLAMMATORY ACTIVITY OF A SERIES OF BETA-AMINOXYPROPIONIC ACIDS 173
Design, Synthesis, Biological Evaluation, and NMR Studies of a New Series of Arylsulfones As Selective and Potent Matrix Metalloproteinase-12 Inhibitors 173
Conformationally restrained β -blocking oxime ethers: synthesis and β -adrenergic properties of diastereoisomeric anti and syn 2-(5-isoxazolidinyl)ethanolamines 172
2-(Methyleneaminoxy)methylmorpholine derivatives. Synthesis and antidepressant activity 171
Selective inhibition of human erythrocyte Na+/K+ ATPase by cardiac glycosides and by a mammalian digitalis like factor 171
Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes 170
Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors 170
Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alfa- and beta-adrenergic receptors 169
Olivetol- and Resorcinol-Anandamide “hybrids”: design, synthesis, binding and molecular modeling of potent cannabinoid receptor ligands 167
Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors 167
Cannabinoid CB2/CB1 Selectivity. Receptor Modeling and Automated Docking Analysis 167
N-O-Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential Therapeutic Agents for Osteoarthritis 167
Selective activators of estrogen receptor beta based on the aldoxime and ketoxime scaffolds 165
Different Binding Modes of Structurally Diverse Ligands for Human D3DAR 165
Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds 165
Conformationally restrained analogues of sympathomimetic catecholamines: Synthesis and adrenergic activity of 5,6- and 6,7-dihydroxy-3,4-dihydrospiro[naphthalen-1(2H)-2′,5′- morpholines] 164
Novel aminopteroil-sulfonamide derivatives as inhibitors of dihydrofolate reductase and carbonic anhydrase, with potential anti tumor activity 164
Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5 164
Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells 163
Development of a Fingerprint-Based Scoring Function for the Prediction of the Binding Mode of Carbonic Anhydrase II Inhibitors 163
N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation 162
Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models 162
An interdisciplinary approach to the design of new structures active at the beta-adrenergic receptor. Aliphatic oxime ether derivatives 161
New Resorcinol-Anandamide "Hybrids" as Potent Cannabinoid Receptor Ligands Endowed with Antinociceptive Activity in Vivo 161
Synthesis and ß-Adrenergic Properties Of (Z)-N-[3-(Alkylamino)-2-hydroxypropilidene](aryl-methyloxy)amines: Effects Of The Configuration Around The Methyloxyiminomethyl(MOIM) Double Bond On The Biopharmacological Properties Of MOIM-type ß-Blocking Agents 159
Computational Studies on Translocator Protein (TSPO) and its Ligands 159
Structure-Activity Relationship Studies of a New Series of Imidazo2,1-fpurinones as Potent and Selective A3 Adenosine Receptor Antagonists 159
Design of transthyretin amyloidosis inhibitors: A docking and virtual screening approach 158
Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: An investigation of the 1,8-naphthyridin-2(1H)-one scaffold 158
1-benzilossiimmino-3- ammino-2-propanoli: sintesi e proprietà ß-adrenergiche 157
Triazole-substituted N-hydroxyindol-2-carboxylates as inhibitors of isoform 5 of human lactate dehydrogenase (hLDH5) 157
N-Hydoxyindoles: novel, selective, and efficient inhibitors of isoform 5 of human lactate dehydrogenase (hLDH-5) 155
Immune-Modulation and Properties of Absorption and Blood Brain Barrier Permeability of 1,8-Naphthyridine Derivatives. 155
Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH) 154
Derivatives of 4-Amino-6-hydroxy-2-mercaptopyrimidine as Novel, Potent, and Selective A3 Adenosine Receptor Antagonists 153
Nuovi agenti ß-bloccanti: Derivati propanolamminici di eteri di ossime completamente alifatiche 151
APPARENT MOLAR SPECIFIC-HEATS OF ORGANIC SOLUTES IN AQUEOUS-SOLUTION 151
Multitemplate Alignment Method for the Development of a Reliable 3D-QSAR Model for the Analysis of MMP3 Inhibitors 151
The cannabinoid CB2/CB1 selectivity. Homology modelling and automated docking analysis 150
Design, synthesis, and biological evaluation of 1,8-naphthyridin-2(1H)-on-3-carboxamide, quinolin-2(1H)-on-3-carboxamide and 2-oxo-1,2-dihydropyridine-3-carboxamide derivatives as CB2 selective ligands 149
Structure-based virtual screening: Identification of novel CB2 receptor ligands 149
MO STUDIES ON THE MECHANISM OF DRUG RECEPTOR INTERACTION .4. INTERACTING CONFORMATIONS OF BETA-ADRENERGIC DRUGS 148
Substituted Pyrazolo3,4-bpyridines as Potent A1 Adenosine Antagonists: Synthesis, Biological Evaluation, and Development of an A1 Bovine Receptor Model 148
Totale 18.872
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.302
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.302
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.121 0 0 0 0 0 82 100 197 154 138 112 338
2021/20222.630 59 197 74 185 450 344 78 145 84 75 167 772
2022/20232.902 374 368 191 275 312 430 28 197 494 21 167 45
2023/20242.193 358 262 267 152 333 386 87 43 41 32 39 193
2024/20256.864 38 252 113 385 687 597 562 415 571 831 727 1.686
2025/20263.879 395 962 883 563 523 553 0 0 0 0 0 0
Totale 33.350